1. Plasminogen activators and their inhibitor in bone tumors and tumor-like damages
- Author
-
N E, Kushlinskii, A I, Yusifov, E S, Gershtein, Y N, Solov'ev, and N N, Trapeznikov
- Subjects
Adult ,Giant Cell Tumor of Bone ,Male ,Osteochondroma ,Osteosarcoma ,Adolescent ,Chondrosarcoma ,Bone Neoplasms ,Sarcoma, Ewing ,Middle Aged ,Urokinase-Type Plasminogen Activator ,Plasminogen Activators ,Cytosol ,Tissue Plasminogen Activator ,Plasminogen Activator Inhibitor 1 ,Humans ,Female ,Child - Abstract
Expression of urokinase- and tissue-type plasminogen activators and their inhibitor PAI-1 in the cytosolic fraction of 20 osteosarcomas, 20 chondrosarcomas, 13 giant-cell bone tumors, 5 Ewing's sarcomas, and 7 osteochondral exostoses was studied by enzyme immunoassay. The content of urokinase-type plasminogen activator increased, while the concentration of tissue-type plasminogen activator decreased in bone tumors of various histological compositions compared to osteochondral exostoses. A positive correlation was found between PAI-1 content and the volume of osteo- and chondrosarcomas. Expression of urokinase-type plasminogen activator increased in patients with primary osteosarcomas characterized by early generalization of the pathological process.
- Published
- 2001